Rp
Republic of the Philippines 08
HOUSE OF REPRESENTATIVES al

Quezon City, Metro Manila

L_2013
Bo

SIXTEENTH CONGRESS
FIRST REGULAR SESSION

HOUSE BILL NO. 1143

INTRODUCED BY: HON. HERNAN G.

RON, JR.

AN ACT ESTABLISHING THE DRUG PRICE REGULATORY BOARD TO.
sULATE THE PRICES OF DRUGS AND MEDICINES IN THE PHILIPPINES.
AMENDING FOR THE PURPOSE REPUBLIC ACT NO. 9502, OTHERWISE KNOWN
AS THE “UNIVERSALLY ACCESSIBLE CHEAPER AND QUALITY MEDICINES
ACT OF 2008” AND FOR OTHER PURPOSES:

EXPLANATORY NOTE

‘This bill proposes to establish the Drug Price Regulatory Board to regulate the pri
drugs and medicines in the Philippines thereby amending RA 9502, otherwise titled
“Universally Accessible Cheaper and Quality Medicines Act of 2008.”

Notwithstanding the fact that the law as signed is already considered “watered down” by
concerned sectors, big pharmaceutical firms are adamant in its effort to diminish its effectiveness
by questioning the setting of a Maximum Retail Price (MRP) on 22 essential drugs out of the
1,600 drugs earlier identified for price regulation. What is alarming is that the 22 drugs under
consideration for price reduction do not even include medications for some of the most common
ailments and medical needs of the citizenry. Thus, it is clear that contrary to its objective, RA
‘9502, will not redound to the benefit of the millions of poor and indigent Filipinos.

Present events prove that without the Drug Price Regulatory Board to regulate prices of
drugs and medicines, it is impossible to lower the prices of essential medicines. It is recalled that
the original bill in the House of Representatives (House Bill No. 01) filed during the 14"

Congress by the undersigned as the principal author contained the Drug Price Regulatory Board

The version of the bill as passed by the House of Representatives with an overwhelming
majority votes expressed the solid sentiment of the House for the establishment of the Price
Regulatory Board. The House version establishing a regulatory mechanism was not contained in
the Senate version authored by Senator Mar Roxas. The Senate version only called for
amendment of the intellectual property Jaw and parallel importation, hoping that prices of
medicines will be lowered by competition.

The conference committee reconciling the provisions of the two bills eliminated the Drug
Price Regulatory Board. In its place, a weak regulatory mechanism was provided by allowing,
the Secretary of Health to recommend to the President of the Philippines the lowering of the
prices of essential medicines. This procedure is circuitous and takes a longer time to lower the
prices of essential medicines.



Since present events proved the superior wisdom of the House version, the undersigned
proponent is persuaded by honest conviction that the present law is not enough and the best

interest of the people can be served by reviving the Drug Price Regulatory Board in the
amendment. -

In view of the foregoing, passage of this bill is earnestly sought.

TERNAN G. BIRON, JR.
4" District, lleilo


Republic of the Philippines
HOUSE OF REPRESENTATIVES
Quezon City, Metro Manila

SIXTEENTH CONGRESS
FIRST REGULAR SESSION

HOUSE BILL NO.

1143

INTRODUCED BY: HON. HERNAN G. BIRON, JR.

AN ACT ESTABLISHING THE DRUG PRICE REGULATORY BOARD TO.
REGULATE THE PRICES OF DRUGS AND MEDICINES IN THE PHILIPPINES
FOR THE PURPOSE REPUBLIC ACT NO. 9502, OTHERWISE KNOWN
AS THE “UNIVERSALLY ACCESSIBLE CHEAPER AND QUALITY MEDICINES.

ACT OF 2008” AND FOR OTHER PURPOSES

Be it enacted by the Senate and the House of Representatives of the Philippines in Congress
assembled:

1502 will be now be titled, “DRUGS AND

SECTION 1. Chapter 3 of Republic Act No.

MEDICINES PRICE REGULATORY BOARD”.

SECTION 2. Section 17 to Section 22 of Republic Act No. 9502 will be amended to

read as follows;
SECTION 17. Creation and Composition of the Drug Prices Regulation Board,

(a) There is hereby created the Drug Prices Regulation Board, which shall be attached to

the Department of Health and composed of seven (7) members as follows:

Secretary of Health or his duly designated representative as chairperson;

a
Q

Secretary of Trade and Industry or his duly designated representative as. vice

chairperson;

Director, Food and Drugs Administration or his duly designated representative as

S

member;

(4) Chairman, Philippine Health Insurance Corporation as member;


(5) One (1) economist from the academe as member; and
(6) Two (2) representatives from the consumers’ sector as members.

(b) The members of the Board representing the academe and the consumers” secto

shalt
be appointed by the President of the Philippines and shall serve for a term of two (2) years:
Provided that the representatives from the consumers’ sector shall not be eligible for

reappointment for another term.

SECTION 18. Powers of the Board- The Board shall have the following powers:

(a) Power to Determine the Maximum Retail Price of Drugs or Medicines Subject to Price

Regulation - (1) Upon application or motu propio when the public interest so requires, the
Board shall have the power to regulate the retail prices of drugs and medicines listed under
Section 19 hereof, including their dosage form and packing, and, in order that they shall be
made available to the public at affordable retail price from the different manufacturers,
importers, traders, distributors, wholesalers or retailers and after a proper determination as
the Board may deem fit, fix from time to time, by publication the maximum retail price at
which such formulations shall be sold;
(2) No retailer shall sell drugs and medicines at a retail price exceeding the maximum
retail price fixed by the Board; Provided that, until the maximum retail price of drugs and
medicines subject to price regulation is fixed by the Board, the retail price thereof shall
be the price which prevailed immediately before the effectivity of this Act and no

manufacturer, importer, trader, distributor, wholesaler or retailer of such drug or

medicine shall sell the same at a retail price exceeding the price prevailing immediately

before the effectivity of this Act.

For purposes hereof, drugs and medicines shall include but not limited to
single- and multi-ingredient medicines included in the Philippine National Drug,

Formulary (PNDF) Essential Drug List and sold under their generic and brand names


(b) Power to Include Other Drugs or Medicines in the List Subject to Price Regulation, — Upon,

application or motu propio when the public interest so requires and after proper

determination, the Board may order the inclusion of drugs and medicines to the list subject to
price regulation under Section 19 hereof.

(c) Power to Implement Cost-Containment and Other Measures, -

1. The Board shall have the power to determine the fair price of drugs or medicines for
Purposes of public health insurance and government procurement; and
2. The Board shall have the power to implement any other measures that the government

may avail of to effectively reduce the cost of drugs or medicines that shall include, but

not limited to, competitive bidding, price-volume negotiations, and other appropriate

mechanisms that influence supply

demand, and expenditures on drugs and medicines.

(d) Power to Impose Administrative Fines and Penalties. — After due notice and hearing, the

sional

Board shall have the power to suspend or revoke the license to operate (LTO), profi

or business license, as the case may be, of any person, manufacturer, importer, trader,

distributor, wholesaler, retailer., or any other entity, and impose administrative fines in such
amount as it may deem reasonable which shall in no case be less than Fifty Thousand pesos
(50,000.00) nor more than Five Million pesos (P5,000,000,00) for violations of the

maximum retail price fixed pursuant to this section.

SECTION 3. Section 19 to Section 22 will be deleted and Section 23 thereof will become

Section 19 and the corresponding numbering for the subsequent sections adjusted accordingly

SECTION 4. Section 26 of RA 9502 will be amended to read as follows:
SECTION 22. Display of Price Fixed by the Board for Drugs or Medicines

may be determined by the

Subject to Price Regulation. ~ (a.) Within a reasonable period
Board, and: Provided, That it conforms to existing drug product labeling requirements, every
manufacturer, importer, distributor, wholesaler, trader, or retailer of a drug and medicine

le shall display the retail price which shall not exceed the maximum retail price

intended for

fixed by the Board. The maximum retail price shall be printed on the label of the immediate

container of the drug and medicine and the minimum pack thereof offered for retail sale with the


words “RETAIL PRICE NOT TO EXCEED” preceding it, and “UNDER DRUG PRICE
REGULATION?” on a red strip provided that in case of a container consisting of smaller
saleable packs, the retail price of such smaller pack shall also be displayed on the label of each
smaller pack and such price shall not be more than the pro-rata retail price of the main pack
rounded off to the nearest centavo.

(b) Within a period as may be determined by the Board from time to time, every
manufacturer, importer, or trader shall issue a price list to wholesalers, distributors, retailers and
to the Board, indicating the retail price, the maximum retail price, and such other information as

may be required by the Board.

SECTION 23. Display of Price and Price List of Drugs or Medicines Excluded
from the List Subject to Price Regulation.- Every manufacturer, importer, trader, distributor,
wholesaler, or retailer of a drug or medicine excluded from the list subject to price regulation
under Section 19 hereof shall display in indelible print mark on the label of the immediate
container of the drug or medicine and the minimum pack thereof offered for retail sale, the words
“NOT UNDER PRICE REGULATION” on a green strip.

SECTION 5. Chapter 8 on Miscellaneous Provisions will be amended and will be read as

follows:
Chapter 8: Amendments to Republic Act 9994 or the Expanded Senior Citizens
Act of 2010.
Section 42. Exemption of drugs and medicines under price regulation from the
“Expanded Senior Citizens Act of 2010” — Drugs and medicines under price regulation as fixed
by the Board will not be included in the grant of twenty percent (20%) discount and exemption
from the value-added tax (VAT) to senior citizens availing the provisions of Republic Act 9994

or the “Expanded Senior Citizens Act of 2010”.

SECTION 6. Separability Clause. — Any portion or provision of this Act that may be

declared unconstitutional or invalid shall not have the effect of nullifying other portions and


provisions hereof as long as such remaining portion or provision can still subsist and be given

effect in their entirety.

\CTION 7. Repealing Clause. — All laws, decrees, executive orders, proclamations and

administrative regulations or parts thereof inconsistent herewith are hereby repealed or modified

accordingly

after its

CTION 8. Effectivity Clause. — This Act shall take effect fifteen (15) di

nin at least two national newspapers of general circulation.